hrcak mascot   Srce   HID

Izlaganje sa skupa

PHARMACOGENETICS AND INTERACTIONS OF ANTIDEPRESSANTS IN THE TREATMENT OF CO-MORBID ILLNESS

Alma Mihaljević-Peleš ; University Department, Clinical Hospital Zagreb, Kišpatićeva 12, Zagreb, Croatia
Marina Šagud ; University Department, Clinical Hospital Zagreb, Kišpatićeva 12, Zagreb, Croatia
Nada Božina ; Clinical Hospital Centre Zagreb, Clinical Institute of Laboratory diagnostic, Kišpatićeva 12, Zagreb, Croatia
Maja Živković ; Neuropsychaitric Hospital “Dr Ivan Barbet”, Popovača, Croatia
Nikolina Jovanović ; University Department, Clinical Hospital Zagreb, Kišpatićeva 12, Zagreb, Croatia

Puni tekst: engleski, pdf (239 KB) str. 399-400 preuzimanja: 325* citiraj
APA 6th Edition
Mihaljević-Peleš, A., Šagud, M., Božina, N., Živković, M. i Jovanović, N. (2009). PHARMACOGENETICS AND INTERACTIONS OF ANTIDEPRESSANTS IN THE TREATMENT OF CO-MORBID ILLNESS. Psychiatria Danubina, 21 (3), 399-400. Preuzeto s https://hrcak.srce.hr/49304
MLA 8th Edition
Mihaljević-Peleš, Alma, et al. "PHARMACOGENETICS AND INTERACTIONS OF ANTIDEPRESSANTS IN THE TREATMENT OF CO-MORBID ILLNESS." Psychiatria Danubina, vol. 21, br. 3, 2009, str. 399-400. https://hrcak.srce.hr/49304. Citirano 07.04.2020.
Chicago 17th Edition
Mihaljević-Peleš, Alma, Marina Šagud, Nada Božina, Maja Živković i Nikolina Jovanović. "PHARMACOGENETICS AND INTERACTIONS OF ANTIDEPRESSANTS IN THE TREATMENT OF CO-MORBID ILLNESS." Psychiatria Danubina 21, br. 3 (2009): 399-400. https://hrcak.srce.hr/49304
Harvard
Mihaljević-Peleš, A., et al. (2009). 'PHARMACOGENETICS AND INTERACTIONS OF ANTIDEPRESSANTS IN THE TREATMENT OF CO-MORBID ILLNESS', Psychiatria Danubina, 21(3), str. 399-400. Preuzeto s: https://hrcak.srce.hr/49304 (Datum pristupa: 07.04.2020.)
Vancouver
Mihaljević-Peleš A, Šagud M, Božina N, Živković M, Jovanović N. PHARMACOGENETICS AND INTERACTIONS OF ANTIDEPRESSANTS IN THE TREATMENT OF CO-MORBID ILLNESS. Psychiatria Danubina [Internet]. 2009 [pristupljeno 07.04.2020.];21(3):399-400. Dostupno na: https://hrcak.srce.hr/49304
IEEE
A. Mihaljević-Peleš, M. Šagud, N. Božina, M. Živković i N. Jovanović, "PHARMACOGENETICS AND INTERACTIONS OF ANTIDEPRESSANTS IN THE TREATMENT OF CO-MORBID ILLNESS", Psychiatria Danubina, vol.21, br. 3, str. 399-400, 2009. [Online]. Dostupno na: https://hrcak.srce.hr/49304. [Citirano: 07.04.2020.]

Sažetak
Patients who require long-term treatment for depression have an increased risk of experiencing drug interactions since they will take medications for and/or co-morbid illness. Antidepressants can be the object of drug interactions by other substances, or they can precipitate interactions by inhibiting enzyme pathways. There is an increasing agreement about the importance of polymorphisms
in cytochrome P450 enzymes and the effects of drug-drug interactions in relation to the incidence of adverse effects. Genetic test suitable for the routine laboratory are now available for some important metabolizing enzymes (e.g. CY2D6, CY2C19)
identifying those individuals who are slow or fast metabolizers of certain drugs.
Specific antidepressants differ in the interactions with CYP450 isoenzymes and in their susceptibility to drug-drug interactions.
The main focus of this article is pharmacokinetic drug interactions of
antidepressants. With that specific knowledge, clinicians can improve outcomes of depressed patients, by considering the possibility of drug interactions both before prescribing a specific antidepressant and while monitoring for response, adverse effects and patient compliance.

Ključne riječi
CYP450 isoenzymes; antidepressants; drug-drug interactions

Hrčak ID: 49304

URI
https://hrcak.srce.hr/49304

Posjeta: 482 *